Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.

MLA

Pfeiffer, Thomas, et al. “Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 29, no. 2, Jan. 2023, pp. 324–30. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-22-2415.

APA

Pfeiffer, T., Tzannou, I., Wu, M., Ramos, C., Sasa, G., Martinez, C., Lulla, P., Krance, R. A., Scherer, L., Ruderfer, D., Naik, S., Bocchini, C., Fraser, I. P., Patel, B., Ward, D., Wang, T., Heslop, H. E., Leen, A. M., & Omer, B. (2023). Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 29(2), 324–330. https://doi.org/10.1158/1078-0432.CCR-22-2415

Chicago

Pfeiffer, Thomas, Ifigeneia Tzannou, Mengfen Wu, Carlos Ramos, Ghadir Sasa, Caridad Martinez, Premal Lulla, et al. 2023. “Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 29 (2): 324–30. doi:10.1158/1078-0432.CCR-22-2415.